• 1
    Angulo P, Deach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 13561362.
  • 2
    Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastoenterology 2000; 118: 11171123.
  • 3
    Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137145.
  • 4
    Bellentani S, Tiribelli C, Saccoccio G et al. Prevalence of chronic liver disease in the general population of Northern Italy: the Dionysos Study. Hepatology 1994; 20: 14421449.
  • 5
    Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the US population. Gastroenterol 2001; 120 (Suppl. 1): 344.
  • 6
    Ludwig J, Viggiano JR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434438.
  • 7
    Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 7480.
  • 8
    Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in non-alcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95: 10561062.
  • 9
    Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 11061110.
  • 10
    Klain J, Fraser D, Goldstein J et al. Liver histology abnormalities in the morbidly obese. Hepatology 1989; 10: 873876.
  • 11
    Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970; 282: 829834.
  • 12
    Moxley RT, Pozefsky T, Lockwood DH. Protein nutrition and liver disease after jejunoileal bypass for morbid obesity. N Engl J Med 1974; 290: 921926.
  • 13
    Hamilton DL, Vest TK, Brown BS, Shah AN, Menguy RB, Chey WY. Liver injury with alcoholic like hyalin after gastroplasty for morbid obesity. Gastroenterology 1983; 85: 722726.
  • 14
    Craig RM, Neumann T, Jeejeehoy KN, Yokoo H. Severe hepatocellular reaction resembling alcoholic hepatitis with cirrhosis after massive small bowel resection and prolonged total parenteral nutrition. Gastroenterology 1980; 79: 131137.
  • 15
    Bower RH. Hepatic complications of parenteral nutrition. Semin Liver Dis 1983; 3: 216224.
  • 16
    Rigas B, Rosenfeld LE, Barwick KW et al. Amiodarone hepatotoxicity. A clinicopathologic study of five patients. Ann Intern Med 1986; 104: 348351.
  • 17
    Poucell S, Ireton J, Valencia-Mayoral P et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984; 86: 926936.
  • 18
    Itoh S, Igarashi M, Tsukada Y, Ichinoe A. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticord therapy. Acta Hepatogastroenterol (Stuttg) 1977; 24: 415418.
  • 19
    Seki K, Minami Y, Nishikawa M et al. ‘Nonalcoholic steatohepatitis’ induced by massive doses of synthetic estrogen. Gastroenterol Jpn 1983; 18: 197203.
  • 20
    Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldmann G. Perhexilene maleate-induced cirrhosis. Gastroenterology 1979; 76: 170177.
  • 21
    Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989; 97: 10221024.
  • 22
    Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia evolution of micronodular cirrhosis. Gastroenterology 1974; 67: 107118.
  • 23
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 11031109.
  • 24
    Caldwell SH, Oelsner DH, Iezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664669.
  • 25
    Cantos MJ, Cales W, Sterling RK et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transplantation 2001; 7: 363373.
  • 26
    Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steer JL, Wiesner RH. Recurrence of non-alcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62: 18021805.
  • 27
    Malloy RM, Komorowski R, Varma RR. Recurrent non-alcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997; 3: 177178.
  • 28
    Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 1997; 3: 174176.
  • 29
    Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation: diabetes, hypercholesterolemia, hypertension and obesity. Transplantation 1995; 60: 10571060.
  • 30
    Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65: 180187.
  • 31
    Klupp J, Glanemann M, Bechstein WO et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 1999; 31: 11131114.
  • 32
    Jain AB, Hamad I, Rakela J et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998; 66: 13951398.
  • 33
    Fisher RA, Ham JM, Marcos A et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998; 66: 16161621.
  • 34
    Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liv Dis 1995; 15: 7081.
  • 35
    Greenson JK, Svoboda-Newman SM, Merion Rm, Frank TS. Histologic progression of recurrent hepatitis C in liver transplant allografts. Am J Surg Pathol 1996; 20: 731738.
  • 36
    Laurin J, Lindor KD, Crippin JS et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 14641467.
  • 37
    Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury. implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 25572562.
  • 38
    Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass: prevention and reversal by metronidazole, irrespective of protein calorie malnutrition. Gastroenterology 1982; 82: 535548.
  • 39
    Nazim M, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology 1989; 36: 379351.
  • 40
    Sakurada M, Okhohchi N, Katoh H et al. Mitochondrial energy synthesis during cold preservation and after reperfusion in liver transplantation. Nippon Geka Gakkai Zasshi 1992; 93: 709715.
  • 41
    Ohkohchi N, Endoh T, Oikawa K, Seya K, Satomi S. Fragility of the electron transport chain and superoxide generation in mitochondria of the liver graft after ischemia. Transplantation 1999; 67: L1173L1177.
  • 42
    Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 5769.
  • 43
    Weltman MD, Farrell GC, Hall P, Ingelman-Sundbert M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128133.
  • 44
    Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998; 28: 410416.
  • 45
    Tsukada H, Wang PY, Kaneko T, Wang Y, Nakano M, Sato A. Dietary carbohydrate intake plays an important role in preventing alcoholic fatty liver in the rat. J Hepatol 1998; 29: 715724.